What Happened to 23andMe? Why Harris’ Plan to Tax Unrealized Gains Makes No Sense, and Time Really is Money
The Prof G Pod with Scott Galloway
00:00
The Rise and Fall of 23andMe: An Investment Cautionary Tale
This chapter examines the struggles of genetic testing company 23andMe, highlighting its dramatic decline from a $4.5 billion valuation to below 50 cents per share. It also covers the lessons on investment strategies and the impact of overexpansion and operational costs on the company's financial health.
Transcript
Play full episode
